ABOUT MAC
Phase I-IV clinical trials excellence
MAC Clinical Research is one of Europe’s largest contract research organisations (CRO), committed to providing full-service delivery of global clinical studies. Headquartered in the UK with offices globally, we conduct studies both through our fully-owned network of dedicated research sites in the UK and through contracting with sites across the globe. We offer the global clinical study management you need to meet your clinical outcome goals. Although our heritage stems from being the first memory assessment centre based in Europe, our company conducts research for sponsors over an ever-expanding group of therapeutic areas. MAC has an extensive range of clinical research capabilities to accommodate the most complex Phase I trials (in our MHRA-accredited Phase I unit Read More) through to Phase IV (across our network of late-phase dedicated research sites). The majority of our current work includes diseases of the central nervous system (CNS), such as Alzheimer's disease and multiple sclerosis, as well as analgesics (acute and chronic pain), dermatology (psoriasis and eczema), rheumatology (fibromyalgia and arthritis), endocrinological diseases (e.g., diabetes), depression, anxiety, and insomnia.
With Eight Dedicated Research Sites across the country (including seven late phase and one MHRA Accredited Phase 1 Unit) MAC has ease of access to over 20 million patients in the UK alone.
MAC’s Recruitment Centre provides excelled recruitment of patients for all studies, often reaching target figures ahead of study timelines. With over 200 clinical studies successfully completed, and extensive therapeutic expertise, MAC’s full-service offering to pharma, biotech and CROs continues to strengthen with significant growth.
MAC's privately owned Dedicated Research Sites provide an efficient and effective option for conducting clinical trials, which avoids unnecessary delays. In fact, MAC's lead-time through the regulatory submissions process currently takes 35 days in total.
